journal
MENU ▼
Read by QxMD icon Read
search

Lancet Oncology

journal
https://www.readbyqxmd.com/read/28081914/safety-and-activity-of-pembrolizumab-in-patients-with-locally-advanced-or-metastatic-urothelial-cancer-keynote-012-a-non-randomised-open-label-phase-1b-study
#1
Elizabeth R Plimack, Joaquim Bellmunt, Shilpa Gupta, Raanan Berger, Laura Q M Chow, Jonathan Juco, Jared Lunceford, Sanatan Saraf, Rodolfo F Perini, Peter H O'Donnell
BACKGROUND: PD-1 and its ligands are expressed in urothelial cancer, and findings have shown that inhibition of the PD-1 pathway has clinical benefit. We aimed to assess the safety and activity of an anti-PD-1 antibody pembrolizumab in patients with locally advanced or metastatic urothelial cancer. METHODS: This study was part of the non-randomised, multi-cohort, open-label, phase 1b KEYNOTE-012 basket trial. We enrolled patients aged 18 years and older with a histologically or cytologically confirmed diagnosis of locally advanced or metastatic urothelial cancer, including cancers of the renal pelvis, ureter, bladder, or urethra, from eight hospitals in the USA and Israel...
January 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28081913/checkpoint-inhibition-a-new-beginning-for-urothelial-cancer
#2
Tracy L Rose, Matthew I Milowsky
No abstract text is available yet for this article.
January 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28017664/cetuximab-chemoradiotherapy-in-hiv-associated-anal-cancer
#3
Manjulika Das
No abstract text is available yet for this article.
December 22, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/28017663/onartuzumab-ineffective-in-non-small-cell-lung-cancer
#4
Vicki Brower
No abstract text is available yet for this article.
December 22, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/28012978/correction-to-lancet-oncol-2016-published-online-dec-16-http-dx-doi-org-10-1016-s1470-2045-16-30648-9
#5
(no author information available yet)
No abstract text is available yet for this article.
December 21, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/28012977/two-stage-implant-based-breast-reconstruction-compared-with-immediate-one-stage-implant-based-breast-reconstruction-augmented-with-an-acellular-dermal-matrix-an-open-label-phase-4-multicentre-randomised-controlled-trial
#6
Rieky E G Dikmans, Vera L Negenborn, Mark-Bram Bouman, Hay A H Winters, Jos W R Twisk, P Quinten Ruhé, Marc A M Mureau, Jan Maerten Smit, Stefania Tuinder, Yassir Eltahir, Nicole A Posch, Josephina M van Steveninck-Barends, Marleen A Meesters-Caberg, René R W J van der Hulst, Marco J P F Ritt, Margriet G Mullender
BACKGROUND: The evidence justifying the use of acellular dermal matrices (ADMs) in implant-based breast reconstruction (IBBR) is limited. We did a prospective randomised trial to compare the safety of IBBR with an ADM immediately after mastectomy with that of two-stage IBBR. METHODS: We did an open-label, randomised, controlled trial in eight hospitals in the Netherlands. Eligible women were older than 18 years with breast carcinoma or a gene mutation linked with breast cancer who intended to undergo skin-sparing mastectomy and immediate IBBR...
December 21, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/28012976/one-stage-versus-two-stage-breast-reconstruction-prudence-in-surgical-decision-making
#7
Alexander J Gougoutas, Benjamin O Anderson
No abstract text is available yet for this article.
December 21, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/28007457/padeliporfin-vascular-targeted-photodynamic-therapy-versus-active-surveillance-in-men-with-low-risk-prostate-cancer-clin1001-pcm301-an-open-label-phase-3-randomised-controlled-trial
#8
Abdel-Rahmène Azzouzi, Sébastien Vincendeau, Eric Barret, Antony Cicco, François Kleinclauss, Henk G van der Poel, Christian G Stief, Jens Rassweiler, Georg Salomon, Eduardo Solsona, Antonio Alcaraz, Teuvo T Tammela, Derek J Rosario, Francisco Gomez-Veiga, Göran Ahlgren, Fawzi Benzaghou, Bertrand Gaillac, Billy Amzal, Frans M J Debruyne, Gaëlle Fromont, Christian Gratzke, Mark Emberton
BACKGROUND: Vascular-targeted photodynamic therapy, a novel tissue-preserving treatment for low-risk prostate cancer, has shown favourable safety and efficacy results in single-arm phase 1 and 2 studies. We compared this treatment with the standard of care, active surveillance, in men with low-risk prostate cancer in a phase 3 trial. METHODS: This randomised controlled trial was done in 47 European university centres and community hospitals. Men with low-risk, localised prostate cancer (Gleason pattern 3) who had received no previous treatment were randomly assigned (1:1) to vascular-targeted photodynamic therapy (4 mg/kg padeliporfin intravenously over 10 min and optical fibres inserted into the prostate to cover the desired treatment zone and subsequent activation by laser light 753 nm with a fixed power of 150 mW/cm for 22 min 15 s) or active surveillance...
December 19, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/28007456/low-risk-prostate-cancer-to-treat-or-not-to-treat
#9
Stephen J Freedland
No abstract text is available yet for this article.
December 19, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27993569/a-genome-based-model-for-adjusting-radiotherapy-dose-gard-a-retrospective-cohort-based-study
#10
Jacob G Scott, Anders Berglund, Michael J Schell, Ivaylo Mihaylov, William J Fulp, Binglin Yue, Eric Welsh, Jimmy J Caudell, Kamran Ahmed, Tobin S Strom, Eric Mellon, Puja Venkat, Peter Johnstone, John Foekens, Jae Lee, Eduardo Moros, William S Dalton, Steven A Eschrich, Howard McLeod, Louis B Harrison, Javier F Torres-Roca
BACKGROUND: Despite its common use in cancer treatment, radiotherapy has not yet entered the era of precision medicine, and there have been no approaches to adjust dose based on biological differences between or within tumours. We aimed to assess whether a patient-specific molecular signature of radiation sensitivity could be used to identify the optimum radiotherapy dose. METHODS: We used the gene-expression-based radiation-sensitivity index and the linear quadratic model to derive the genomic-adjusted radiation dose (GARD)...
December 18, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27993570/radiation-oncology-enters-the-era-of-individualised-medicine
#11
Philip Poortmans, Orit Kaidar-Person, Paul Span
No abstract text is available yet for this article.
December 16, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27989428/san-antonio-breast-cancer-symposium-2016
#12
Katherine Gourd
No abstract text is available yet for this article.
December 15, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27956157/ibrutinib-for-patients-with-rituximab-refractory-waldenstr%C3%A3-m-s-macroglobulinaemia-innovate-an-open-label-substudy-of-an-international-multicentre-phase-3-trial
#13
Meletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, Jeffrey V Matous, David Macdonald, Constantine Tam, Olivier Tournilhac, Shuo Ma, Albert Oriol, Leonard T Heffner, Chaim Shustik, Ramón García-Sanz, Robert F Cornell, Carlos Fernández de Larrea, Jorge J Castillo, Miquel Granell, Marie-Christine Kyrtsonis, Veronique Leblond, Argiris Symeonidis, Efstathios Kastritis, Priyanka Singh, Jianling Li, Thorsten Graef, Elizabeth Bilotti, Steven Treon, Christian Buske
BACKGROUND: In the era of widespread rituximab use for Waldenström's macroglobulinaemia, new treatment options for patients with rituximab-refractory disease are an important clinical need. Ibrutinib has induced durable responses in previously treated patients with Waldenström's macroglobulinaemia. We assessed the efficacy and safety of ibrutinib in a population with rituximab-refractory disease. METHODS: This multicentre, open-label substudy was done at 19 sites in seven countries in adults aged 18 years and older with confirmed Waldenström's macroglobulinaemia, refractory to rituximab and requiring treatment...
December 9, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27956155/ibrutinib-in-waldenstr%C3%A3-m-s-macroglobulinemia-revamping-the-landscape
#14
Bruce D David Cheson
No abstract text is available yet for this article.
December 9, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27932068/rovalpituzumab-tesirine-a-dll3-targeted-antibody-drug-conjugate-in-recurrent-small-cell-lung-cancer-a-first-in-human-first-in-class-open-label-phase-1-study
#15
Charles M Rudin, M Catherine Pietanza, Todd M Bauer, Neal Ready, Daniel Morgensztern, Bonnie S Glisson, Lauren A Byers, Melissa L Johnson, Howard A Burris, Francisco Robert, Tae H Han, Sheila Bheddah, Noah Theiss, Sky Watson, Deepan Mathur, Bharathi Vennapusa, Hany Zayed, Satwant Lally, Donald K Strickland, Ramaswamy Govindan, Scott J Dylla, Stanford L Peng, David R Spigel
BACKGROUND: Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), a novel target identified in tumour-initiating cells and expressed in more than 80% of patients with small-cell lung cancer. We aimed to assess the safety and activity of rovalpituzumab tesirine in patients who progressed after one or more previous regimen. METHODS: We conducted a phase 1 open-label study at ten cancer centres in the USA...
December 2, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27932066/raising-the-bar-on-first-line-immunotherapy-in-lung-cancer
#16
Jessica J Lin, Alice T Shaw
No abstract text is available yet for this article.
December 2, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27927582/clonal-haemopoiesis-and-therapy-related-myeloid-malignancies-in-elderly-patients-a-proof-of-concept-case-control-study
#17
Nancy K Gillis, Markus Ball, Qing Zhang, Zhenjun Ma, YuLong Zhao, Sean J Yoder, Maria E Balasis, Tania E Mesa, David A Sallman, Jeffrey E Lancet, Rami S Komrokji, Alan F List, Howard L McLeod, Melissa Alsina, Rachid Baz, Kenneth H Shain, Dana E Rollison, Eric Padron
BACKGROUND: Clonal haemopoiesis of indeterminate potential (CHIP) is an age-associated genetic event linked to increased risk of primary haematological malignancies and increased all-cause mortality, but the prevalence of CHIP in patients who develop therapy-related myeloid neoplasms is unknown. We did this study to investigate whether chemotherapy-treated patients with cancer who have CHIP are at increased risk of developing therapy-related myeloid neoplasms. METHODS: We did a nested, case-control, proof-of-concept study to compare the prevalence of CHIP between patients with cancer who later developed therapy-related myeloid neoplasms (cases) and patients who did not develop these neoplasms (controls)...
December 2, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27927581/predicting-therapy-related-myeloid-neoplasms-and-preventing-them
#18
David P Steensma
No abstract text is available yet for this article.
December 2, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27923552/preleukaemic-clonal-haemopoiesis-and-risk-of-therapy-related-myeloid-neoplasms-a-case-control-study
#19
Koichi Takahashi, Feng Wang, Hagop Kantarjian, Denaha Doss, Kanhav Khanna, Erika Thompson, Li Zhao, Keyur Patel, Sattva Neelapu, Curtis Gumbs, Carlos Bueso-Ramos, Courtney D DiNardo, Simona Colla, Farhad Ravandi, Jianhua Zhang, Xuelin Huang, Xifeng Wu, Felipe Samaniego, Guillermo Garcia-Manero, P Andrew Futreal
BACKGROUND: Therapy-related myeloid neoplasms are secondary malignancies that are often fatal, but their risk factors are not well understood. Evidence suggests that individuals with clonal haemopoiesis have increased risk of developing haematological malignancies. We aimed to identify whether patients with cancer who have clonal haemopoiesis are at an increased risk of developing therapy-related myeloid neoplasms. METHODS: We did this retrospective case-control study to compare the prevalence of clonal haemopoiesis between patients treated for cancer who later developed therapy-related myeloid neoplasms (cases) and patients who did not develop these neoplasms (controls)...
December 2, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27916398/ruxolitinib-for-the-treatment-of-inadequately-controlled-polycythaemia-vera-without-splenomegaly-response-2-a-randomised-open-label-phase-3b-study
#20
Francesco Passamonti, Martin Griesshammer, Francesca Palandri, Miklos Egyed, Giulia Benevolo, Timothy Devos, Jeannie Callum, Alessandro M Vannucchi, Serdar Sivgin, Caroline Bensasson, Mahmudul Khan, Nadjat Mounedji, Guray Saydam
BACKGROUND: In the pivotal RESPONSE study, ruxolitinib, a Janus kinase (JAK)1 and JAK2 inhibitor, was superior to best available therapy at controlling haematocrit and improving splenomegaly and symptoms in patients with polycythaemia vera with splenomegaly who were inadequately controlled with hydroxyurea. In this study, we assessed the efficacy and safety of ruxolitinib in controlling disease in patients with polycythaemia vera without splenomegaly who need second-line therapy. METHODS: RESPONSE-2 is a randomised, open-label, phase 3b study assessing ruxolitinib versus best available therapy in patients with polycythaemia vera done in 48 hospitals or clinics across 12 countries in Asia, Australia, Europe, and North America...
December 1, 2016: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"